Suppr超能文献

肠道胆汁酸转运体在胆汁酸和药物处置中的作用。

Role of the intestinal bile acid transporters in bile acid and drug disposition.

作者信息

Dawson Paul A

机构信息

Department of Internal Medicine, Section on Gastroenterology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157, USA.

出版信息

Handb Exp Pharmacol. 2011(201):169-203. doi: 10.1007/978-3-642-14541-4_4.

Abstract

Membrane transporters expressed by the hepatocyte and enterocyte play critical roles in maintaining the enterohepatic circulation of bile acids, an effective recycling and conservation mechanism that largely restricts these potentially cytotoxic detergents to the intestinal and hepatobiliary compartments. In doing so, the hepatic and enterocyte transport systems ensure a continuous supply of bile acids to be used repeatedly during the digestion of multiple meals throughout the day. Absorption of bile acids from the intestinal lumen and export into the portal circulation is mediated by a series of transporters expressed on the enterocyte apical and basolateral membranes. The ileal apical sodium-dependent bile acid cotransporter (abbreviated ASBT; gene symbol, SLC10A2) is responsible for the initial uptake of bile acids across the enterocyte brush border membrane. The bile acids are then efficiently shuttled across the cell and exported across the basolateral membrane by the heteromeric Organic Solute Transporter, OSTα-OSTβ. This chapter briefly reviews the tissue expression, physiology, genetics, pathophysiology, and transport properties of the ASBT and OSTα-OSTβ. In addition, the chapter discusses the relationship between the intestinal bile acid transporters and drug metabolism, including development of ASBT inhibitors as novel hypocholesterolemic or hepatoprotective agents, prodrug targeting of the ASBT to increase oral bioavailability, and involvement of the intestinal bile acid transporters in drug absorption and drug-drug interactions.

摘要

肝细胞和肠细胞表达的膜转运蛋白在维持胆汁酸的肠肝循环中起着关键作用,这是一种有效的再循环和保存机制,在很大程度上限制了这些潜在的细胞毒性去污剂进入肠道和肝胆系统。通过这种方式,肝脏和肠细胞转运系统确保全天多餐消化过程中能持续供应可反复使用的胆汁酸。胆汁酸从肠腔的吸收以及进入门静脉循环是由肠细胞顶端和基底外侧膜上表达的一系列转运蛋白介导的。回肠顶端钠依赖性胆汁酸共转运蛋白(缩写为ASBT;基因符号,SLC10A2)负责胆汁酸跨肠细胞刷状缘膜的初始摄取。然后,胆汁酸通过异源有机溶质转运体OSTα-OSTβ有效地穿梭过细胞并从基底外侧膜输出。本章简要回顾了ASBT和OSTα-OSTβ的组织表达、生理学、遗传学、病理生理学和转运特性。此外,本章还讨论了肠道胆汁酸转运蛋白与药物代谢之间的关系,包括开发ASBT抑制剂作为新型降胆固醇或肝保护剂、将ASBT作为前药靶点以提高口服生物利用度,以及肠道胆汁酸转运蛋白在药物吸收和药物相互作用中的作用。

相似文献

1
Role of the intestinal bile acid transporters in bile acid and drug disposition.
Handb Exp Pharmacol. 2011(201):169-203. doi: 10.1007/978-3-642-14541-4_4.
2
The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter.
J Biol Chem. 2005 Feb 25;280(8):6960-8. doi: 10.1074/jbc.M412752200. Epub 2004 Nov 24.
3
The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis.
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3891-6. doi: 10.1073/pnas.0712328105. Epub 2008 Feb 21.
4
Targeting the Four Pillars of Enterohepatic Bile Salt Cycling; Lessons From Genetics and Pharmacology.
Hepatology. 2021 Jun;73(6):2577-2585. doi: 10.1002/hep.31651. Epub 2021 May 24.
5
Expression of Bile Acid Receptors and Transporters Along the Intestine of Patients With Type 2 Diabetes and Controls.
J Clin Endocrinol Metab. 2025 Feb 18;110(3):e660-e666. doi: 10.1210/clinem/dgae261.
6
Bile acid transporters: structure, function, regulation and pathophysiological implications.
Pharm Res. 2007 Oct;24(10):1803-23. doi: 10.1007/s11095-007-9289-1. Epub 2007 Apr 3.
7
Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.
Mol Pharm. 2006 May-Jun;3(3):223-30. doi: 10.1021/mp060022d.
8
Bile acid transporters.
J Lipid Res. 2009 Dec;50(12):2340-57. doi: 10.1194/jlr.R900012-JLR200. Epub 2009 Jun 4.
9
Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE⁻/⁻ mice.
Atherosclerosis. 2013 Aug;229(2):374-80. doi: 10.1016/j.atherosclerosis.2013.05.017. Epub 2013 May 28.

引用本文的文献

1
Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs.
Molecules. 2025 Jul 21;30(14):3053. doi: 10.3390/molecules30143053.
2
The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications.
Front Pharmacol. 2025 Jan 9;15:1510080. doi: 10.3389/fphar.2024.1510080. eCollection 2024.
4
Effects of Several Bile Acids on the Production of Virulence Factors by .
Life (Basel). 2024 Dec 18;14(12):1676. doi: 10.3390/life14121676.
6
Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation.
Acta Pharm Sin B. 2024 Sep;14(9):3876-3900. doi: 10.1016/j.apsb.2024.06.015. Epub 2024 Jun 22.
8
Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases.
Med Rev (2021). 2024 Jun 4;4(4):262-283. doi: 10.1515/mr-2024-0020. eCollection 2024 Aug.
9
Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer.
Cancer Cell Int. 2024 Jun 18;24(1):213. doi: 10.1186/s12935-024-03403-4.

本文引用的文献

3
Bile salts of vertebrates: structural variation and possible evolutionary significance.
J Lipid Res. 2010 Feb;51(2):226-46. doi: 10.1194/jlr.R000042. Epub 2009 Jul 28.
4
The role of transporters in the pharmacokinetics of orally administered drugs.
Pharm Res. 2009 Sep;26(9):2039-54. doi: 10.1007/s11095-009-9924-0. Epub 2009 Jun 30.
5
Bile acid transporters.
J Lipid Res. 2009 Dec;50(12):2340-57. doi: 10.1194/jlr.R900012-JLR200. Epub 2009 Jun 4.
8
Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol.
J Biol Chem. 2009 Jul 17;284(29):19211-9. doi: 10.1074/jbc.M109.014860. Epub 2009 May 5.
9
Genome-wide association meta-analysis for total serum bilirubin levels.
Hum Mol Genet. 2009 Jul 15;18(14):2700-10. doi: 10.1093/hmg/ddp202. Epub 2009 May 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验